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A B S T R A C T
Controlling microarchitecture in polymer scaffolds is a priority in material design for soft tissue
applications. This paper reports for the ﬁrst time the elaboration of alginate foam-based scaffolds for
mesenchymal stem cell (MSC) delivery and a comparative study of various surfactants on the ﬁnal device
performance. The use of surfactants permitted to obtain highly interconnected porous scaffolds with
tunable pore size on surface and in cross-section. Their mechanical properties in compression appeared
to be adapted to soft tissue engineering. Scaffold structures could sustain MSC proliferation over 14 days.
Paracrine activity of scaffold-seeded MSCs varied with the scaffold structure and growth factors release
was globally improved in comparison with control alginate scaffolds. Our results provide evidence that
exploiting different surfactant types for alginate foam preparation could be an original method to obtain
biocompatible scaffolds with tunable architecture for soft tissue engineering.
1. Introduction
For the past decades, there has been a growing interest in the
use of Mesenchymal Stem Cells (MSCs) to regenerate biological
tissues after several acute and chronic diseases. After an initial
focus on their capacity to differentiate into mesodermal lineage,
they are now acknowledged for their positive effects attributed to
their paracrine activities, which allow direct regeneration as well
as indirect modulatory effects on damaged and diseased tissues.
MSCs secrete paracrine factors which promote tissue repair,
stimulate proliferation and differentiation of endogenous tissue
progenitors, and decrease inﬂammatory/immune reactions
(Caplan, 2007; Li and Ikehara, 2013; Souidi et al., 2013). Such
therapeutic properties are particularly effective in ischemic
diseases treatment of the heart (Léobon et al., 2009; Panﬁlov
et al., 2013), kidneys (Alfarano et al., 2012; Furuichi et al., 2012) and
lungs (Chen et al., 2012; Yip et al., 2013). In these treatments, MSCs
are delivered to the targeted organ by injection into the perfusing
artery or directly into the tissue surrounding the damaged area.
Unfortunately, beneﬁts of such therapeutic approaches are limited
by poor cell retention and early cell death at the injury site after
implantation. Indeed, several studies have reported that more than
80–90% of transplanted cells die within the ﬁrst 72 h after injection
(Maurel et al., 2005; Toma et al., 2002). Multiple mechanisms are
involved in these early cell losses including hypoxia, local
inﬂammation and mechanical stress occurring during cell admin-
istration. Improvement of cell concentration and viability at the
injury site, in order to promote their therapeutic activity, is
becoming a priority in the ﬁeld of cell therapy.
One promising strategy is to associate MSCs with a biocompat-
ible material that protects and concentrates them on the damaged
area. The ideal scaffold should improve viability of grafted MSCs,
preserve their paracrine activity and provide an artiﬁcial matrix
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allowing medium/long term cell survival as well as their secretion
function. In addition, the mechanical properties of the selected
material must not only be compatible with soft tissues but also
appropriate for surgery manipulations during implantation on the
damaged tissue. Scaffold architecture is another critical parameter
that could affect the biological activity of entrapped cells and the
fate of the implanted device. More speciﬁcally, it has been reported
that pore size distribution and pore interconnectivity affect cell
morphogenesis (Zmora et al., 2002), stem cell behavior and
implant's colonization by host cells (Salem et al., 2002; Souidi et al,
2013; Toma et al., 2002; Zeltinger et al., 2001).
Among materials used for cell therapy, natural polymers seem
to be particularly adapted in terms of biocompatibility (Lee and
Mooney, 2001). In that regard, alginates are among the most
widely used polymers (Andersen et al., 2015; Bidarra et al., 2014;
Giovagnoli et al., 2015; Ruvinov and Cohen, 2016; Silva et al., 2015 )
due to their low toxicity after puriﬁcation, gelling properties
(under conditions compatible with biological activities: 37 !C, pH
7.4 . . . ), structural resemblance to the extracellular matrix
(considered to be at the origin of their excellent biocompatibility),
and relatively low cost. Regarding their origin and chemical
structure, alginates are naturally occurring anionic linear (un-
branched) polysaccharides, which can be extracted from kelp,
brown seaweed and some bacteria. They are salts of alginic acid
consisting of 1,4-linked b-D-mannuronic (M) and a-L-guluronic (G)
residues organized in regions of sequential G units (G-blocks),
regions of sequential M units (M-blocks) and regions of G and M
units atactically organized. Their sol–gel transition properties are
based on the formation of a stiff “egg-box” structure due to
divalent cations selective binding to the G-blocks of two adjacent
polymeric chains (Grant et al., 1973). The major issue limiting the
widespread use of alginate hydrogels as tissue engineering
scaffolds is the possible exchange of divalent cations with
monovalent cations over time (Bajpai and Sharma, 2004), resulting
in crosslinks dissociations in the gel's network followed by a
mechanical degradation. However, alginates’ mechanical behavior
is easily modiﬁable by different crosslinking or by changing the
type and/or the molecular weight distribution to match the
required stiffness of host tissues (Augst et al., 2006). Moreover, the
degradation rate depends not only on alginates’ characteristics, but
also on the device's dimensions and implantation site. For
example, alginate microspheres injected under the renal capsule
were almost intact 4 weeks after implantation (Trouche et al.,
2010); it was also the case for G-type alginate scaffolds implanted
on rat myocardium but not for M-type alginate scaffolds (Ceccaldi
et al., 2012). Thus, an accurate choice of alginate type/properties
could allow a wide range of biomedical applications.
The biocompatibility of alginates has been extensively described
in the literature and for the last few decades, the scientiﬁc
community has worked to established efﬁcient methods to produce
alginates with high puriﬁcation grades and limited amount of
polyphenols, endotoxins and protein residues which can impact the
inﬂammatory reaction after implantation (Klock et al., 1997;
Leinfelder et al., 2003; Tam et al., 2006). In general, alginates are
not known to be biologically active. In fact, protein adsorption and
cell attachment are low due to their high water content, dense
negative surface charge, and the lack of molecular recognition by cell
surface receptors (Dvir-Ginzberg et al., 2008; Gandhi et al., 2013;
Glicklis et al., 2000). This particularity of alginates, combined with
their strictly local effect (on the application site), have allowed the
material to be qualiﬁed as safe for human application. Furthermore,
several clinical trials using alginate-based medical devices are
currently in progress (AUGMENT-HF: NCT01311791; PRESERVATION
1: NCT01226563; NCT01734733; NCT00521937) or completed (GLP-
1 CellBeads1: NCT01298830; DIABECELL1: NCT00940173;
NCT01396304), demonstrating the growing interest in the use of
this polymer for biomedical applications.
Regarding tissue engineering applications, macroporous three-
dimensional (3D) alginate scaffolds are of particular interest.
Indeed, compared to non-macroporous hydrogels they provide to
cells a biomimetic environment, allow improved cell inﬁltration,
better diffusion of solutes, nutrients and oxygen, as well as
enhanced waste removal (Shapiro and Cohen, 1997). Additionally,
despite the non-adhesive nature of alginate polymers, cells are
efﬁciently incorporated and retained within 3D alginate sponges
due to the porous structure of the matrix whereas they are not on
bi-dimensional (2D) alginate ﬁlms (Dvir-Ginzberg et al., 2008;
Glicklis et al., 2000). A number of studies have shown beneﬁts
when using alginate macroporous scaffolds for 3D cell culture
(Sapir et al., 2011; Caplan, 2007; Li and Ikehara, 2013; Shachar and
Cohen, 2003; Shapiro and Cohen, 1997; Zieber et al., 2014) and for
soft tissues regeneration (Dvir et al., 2009; Dvir-Ginzberg et al.,
2008; Leor et al., 2000). In particular, foaming alginates has
allowed obtaining highly porous scaffolds with tunable morphol-
ogy and mechanical characteristics according to the type and
concentration of alginate used as well as the source of gelling ions
(Andersen et al., 2012, 2014a). In addition, alginate foams appeared
to be highly compatible for cell entrapment, prolonged 3D cell
culture and retrieval of NHIK 3025 and NIH: 3T3 cells (Andersen
et al., 2014b). In our study, we wished to produce foam-based
alginate porous scaffolds speciﬁcally adapted for MSC use in cell
therapy, i.e. tailored for MSC immobilization and improvement of
their secretion ability. For alginate foaming, we have chosen to use
surfactants coming from the polysorbates (Montanox1) and the
poloxamers (Pluronic1) families, as they are non-ionic, water
soluble (hydrophilic–lipophilic balance >8), biocompatible, and
certiﬁed for biomedical applications (Andersen et al., 2012; Bueno
et al., 2014; Eiselt et al., 2000; Fowler et al., 2002; Inzana et al.,
2014; Tadros, 2005; Vashi et al., 2008). More precisely, we used
four of these surfactants as we had observed them to be compatible
with MSC culture (based on a preliminary evaluation of their
cytotoxicity and water solubility): Montanox 20, Montanox 80,
Pluronic 127 and Pluronic 108. Mixing each one of them with an
alginate solution followed by a freeze-drying, permitted the
generation of four different foam-based scaffolds. They were
characterized with regard to their architecture, porosity, mechani-
cal properties and cell-seeding ability with functional MSCs.
Finally, cell viability as well as cell secretion function were also
investigated in order to ascertain the most promising formulations
for soft tissue cell therapy.
2. Materials and methods
Ultrapure MVG sodium alginate with a M/G ratio of 0.47
(determined by 1H NMR measurement) was purchased from
Provona Biopolymer Inc. (Novamatrix, Norway). Sodium bicarbon-
ate was furnished by Cooper (France). Montanox and Pluronic
surfactants were provided by Seppic (France) and BASF Corpora-
tion (France), respectively. HEPES (4-(2-hydroxyethyl)-1-pipera-
zineethanesulfonic acid) sodium salt was purchased form Sigma–
Aldrich, France. Sodium chloride (NaCl) and calcium chloride
dehydrate (CaCl2"2H2O) were purchased from VWR. Reagents used
for in vitro cell culture were a-Minimum Essential Medium
(a-MEM, Invitrogen, San Diego, CA, USA) supplemented with 10%
fetal calf serum (Hyclone, Logan, UT, USA) and ciproﬂoxacin
(10 mg ml#1; Bayer Schering Pharma, Germany).
2.1. Macroporous scaffolds elaboration
Solutions of 3% (w/w) MVG alginate were prepared in iso-
osmotic saline solution during 30 min at 1800–2000 rpm
(Heidolph RZR-2041, Germany). 0.9% (w/w) sodium bicarbonate
and 1% (w/w) surfactant (Montanox 80, Montanox 20, Pluronic
F127 or Pluronic F108) were added and stirred during 30 min to
incorporate air bubbles until a stable foam was obtained.
Three-dimensional scaffolds were generated by a freeze-drying
technique. Brieﬂy, aliquots (500 ml) of the polymer solutions were
placed in a 48-well plate, frozen overnight at #20 !C, and
lyophilized. The constructs were then cross-linked in an iso-
osmotic buffer containing calcium ions (150 mM NaCl, 0.1 M
CaCl2"2H2O, 10% w/w acetic acid) during 30 min. The obtained
scaffolds were washed 3 times (10 min each) in a HEPES buffer and
lyophilized again. All studied scaffolds were prepared under
aseptic conditions and ﬁnally exposed to UV light. The ﬁnal
scaffolds dimensions, used in all experiments, were 10 mm
diameter $ 5 mm thickness.
2.2. Foam stability evaluation
Foam stability was evaluated by measuring the foam volume in
a graduated test tube at determined time intervals. Results are
expressed as a percentage of the ﬁnal foam volume measured 24 h
after preparation.
2.3. Scanning electron microscopy (SEM)
SEM analyses of surfaces and cross-sections of dried 3D
scaffolds were performed with a Leo 435 VP scanning electron
microscope. Samples were mounted on an aluminum sample
mount and sputter-coated with silver. The specimens were
observed at a 10 kV accelerating voltage.
2.4. Computed X-ray micro-tomography (micro-CT)
The micro-CT study of samples was carried out on Phoenix
Nanotom 180 (GE Sensing, Germany) using the following
parameters: 30 kV voltage, 160 mA current, no ﬁlter material,
0.25! rotation step, 5 frames as frame averaging, 1440 tomographic
projections over a 360! scan angle, 1 s exposure time. A binning
2 $ 2 was applied for the slices reconstruction and the resulting
voxel size was 11.5 mm3. 3D virtual models of scaffolds were
obtained using VGStudio MAX 2.1. A region of interest (ROI) was
drawn within the reconstructed volume and a threshold was
deﬁned to identify the polymeric phase. Then, a morphometric
analysis of the ROI was performed to obtain the total porosity and
voids interconnectivity. Scaffolds’ morphologies were analyzed on
the basis of 2D X-ray tomographic slicesusing ImageJ (NIH, USA).
Calculations were done on a ROI deﬁned on the surface and in the
cross-section of each scaffold. Feret’s diameters were obtained and
pore densities were calculated as the total void number/ROI area
(n = 10 slices per scaffold). Voids on edges were excluded.
2.5. Evaluation of scaffolds stability upon rehydration
Scaffolds swelling behavior was evaluated by weighing them
every 10 min after immersion in cell culture medium. The swelling
ratio was calculated according to the following formula:
Swelling ratio ¼
ðWt # W0Þ
W0
where Wt is the scaffold weight at time t and W0 is the weight of
the dried scaffold before placing it in culture medium.
2.6. Fourier transform infrared spectroscopy (FTIR)
Dried samples were mixed with KBr (Fluka, France) and pressed
into a pellet. FITR spectra were recorded between 400 and
4000 cm#1 using Spectrum One FT-IR Spectrometer (Perkin Elmer,
France).
2.7. Mechanical properties evaluation
Differential elastic moduli and mechanical behavior of the
scaffolds were followed by three successive uniaxial compressive
assays (TA-XT2 Texture Analyzer, Stable Microsystems, UK). The
apparatus consisted of a mobile probe (314.16 mm2) moving
vertically up and down at a constant and predeﬁned velocity
(0.5 mm s#1). The force exerted by the probe on the scaffolds was
recorded as a function of the displacement. Then, the force was
converted into stress by reporting the force to the surface of force
application and the displacement was converted to a strain
percentage in comparison with the initial dimension. Differential
elastic moduli were calculated from the stress–strain curves at 50%
of strain and represent the relative stiffness of the scaffold at 50%
strain. The differential elastic modulus was expressed as follows
from at least three independent observations: E50%= [(F50%/S)/
Strain] $ 1000 kPa, where F50% is the force registered at 50% strain
(N) and S is the surface of the specimen (mm2).
2.8. Isolation and culture of human MSCs for in vitro experiments
Human MSCs were isolated from PBS-washed ﬁlters used
during bone marrow graft processing for allogenic bone marrow
transplantation. Cells were cultured at a density of 5 $104 cells
cm#2 in a-Minimum Essential Medium supplemented with 10%
fetal calf serum and ciproﬂoxacin (10 mg ml#1). After 72 h at 37 !C
in 5% CO2, non-adherent cells were removed and the medium was
changed. Cultures were fed every 3–4 days. MSCs were used
between the 3rd and the 6th passage.
2.9. MSC seeding and cultivation
For in vitro studies, cells were seeded within the scaffolds by
centrifugation (400 g, 1 min) after dropping 15 ml of cell suspen-
sion containing 20,000 cells on the top of the dried scaffolds (n = 3
for each experimental condition). The cell-seeded scaffolds were
hydrated by adding 985 ml of culture medium to each scaffold. The
constructs were cultured at 37 !C in 5% CO2 and the medium was
changed every 3–4 days.
2.10. LIVE/DEAD assay and confocal microscopy
LIVE/DEAD assays were performed using the Viability/Cytotox-
icity kit (FluoProbes1, Interchim, France). Brieﬂy, 4 h after seeding,
constructs were washed two times with a-MEM/physiological
serum (1/1) and immersed (30 min, 37 !C) in the presence of 2 mM
ethidium homodimer-3 (necrotic marker measuring nucleus
membrane integrity) and 1 mM calcein AM (viability marker
measuring the intracellular esterase activity) to stain dead cells in
red and live cells in green. After a washing with physiological
serum, scaffolds were observed under a confocal microscope (Zeiss
LSM 510) using a $10 objective. Samples were excited with a
488 nm Argon laser and with a 543 nm helium–neon laser. The
emitted ﬂuorescence was collected using two separate photo
multiplier tubes with a BP 500–560 nm ﬁlter for calcein detection
and a LP 620 nm ﬁlter for ethidium homodimer-3 detection.
2.11. Quantiﬁcation of MSC metabolism activity
Cell metabolism activity was quantiﬁed by AlamarBlue1 assay
(Molecular Probes, Invitrogen, France). 3D scaffolds were trans-
ferred to new wells and incubated with 1 ml of a-MEM
supplemented with 10% of AlamarBlue1 reagent for 1–4 h as
speciﬁed by the manufacturer. Aliquots of 100 ml were transferred
to a 96-well plate and the ﬂuorescence was measured at an
excitation wavelength of 540 nm and an emission wavelength of
620 nm using a plate reader (Inﬁnite1200Pro, Tecan Group).
2.12. Growth factors release quantiﬁcation
After cell seeding, scaffolds were hydrated by adjusting the
volume of culture medium and cultured at 37 !C in 5% CO2 for 24 h
under sterile conditions. The amount of HGF, FGF-2 and VEGF
released into the medium was quantiﬁed in the supernatant by
xMAP technology (Luminex 100TM system, Luminex Corp.) with
anti-human HGF, FGF-2 and VEGF antibodies (Ozyme, France).
2.13. Statistical analysis
Results are expressed as mean ( SEM. Statistical comparison of
the data was performed using one-way ANOVA and post hoc
Bonferroni's test for comparison of more than two groups. For the
mechanical tests, a two-way ANOVA was used to analyze changes
over time among the experimental groups. A value of P < 0.05 was
considered signiﬁcant.
3. Results
3.1. Stability of alginate foams prepared using various surfactants
Alginate foams were produced by mixing 3% (w/w) alginate
solution with bicarbonate and 4 various surfactants as foam
stabilizers: Montanox 80, Montanox 20, Pluronic F127 or Pluronic
F108. The foams stability was studied after 30 min of mixing at
1800–2000 rpm and Fig.1 shows the stability of the foam over time
during 6 h. Foams were stable for all formulations tested, showing
that the 4 surfactants selected for this study are adapted to prepare
foam-based scaffolds after gelation and drying steps.
3.2. Morphology and porosity of alginate foam-based scaffolds
Four different scaffolds with a constant alginate concentration
(3% w/w) were prepared in the presence of Montanox 80,
Montanox 20, Pluronic F127 or Pluronic F108 surfactants, as
described in Section 2. Control scaffolds composed by pure alginate
(without surfactants) were also prepared, according to the same
procedure. Fig. 2 shows SEM images of the surface and the
cross-section of control alginate scaffolds (REF-S, Fig. 2A and F),
and of alginate scaffolds obtained in the presence of Montanox 80
(Mx80-S: Fig. 2B and G), Montanox 20 (Mx20-S: Fig. 2C and H),
Pluronic F127 (F127-S: Fig. 2D and I) and Pluronic F108 (F108-S:
Fig. 2E and J).
SEM micrographs presented in Fig. 2 reveal a highly porous and
interconnected morphology both on surface and in cross-section of
all freeze-dried scaffolds. Quantitative data obtained by micro-CT
shows that the mean pore size ranged from 100 to 200 mm on
surface, and from 100 to 230 mm in cross-section, depending on
the surfactant used in the preparation step. The highest pore
density was obtained using Pluronic 108 and the lowest pore
density was obtained using Montanox 20 and Pluronic 127, both on
surface and in cross-section (Fig. 2K and L). The total porosity
spanned from 80% to 98% (Table 1) and the voids interconnectivity
was 100% for all scaffolds, meaning that all pores were connected
to the surface (data not shown). It is interesting to notice the
variety of 3D porous architectures of the scaffolds generated by
using two different families of surfactants (Montanox and
Pluronic) compared to each other and to the reference scaffold
without surfactant (Fig. 3A and B).
3.3. Presence of surfactant residues within 3D scaffolds
Surfactants are amphiphilic molecules and are therefore able of
inserting into the plasma membrane of the entrapped cells.
Consequently, it is indispensable to wash the scaffolds after
preparation in order to eliminate all surfactant residues. Scaffolds
were washed 3 times in HEPES buffer bath and residues of
surfactant were tracked by FITR. To that end, we ﬁrst determined
wavenumbers of speciﬁc infrared peaks of each surfactant and
then checked their absence in the ﬁnal scaffolds spectra. Their
characteristic peaks were situated at 2859 cm#1 and 1105 cm#1 for
Montanox 80; 2869 cm#1, 1732 cm#1, 1460 cm#1, 1346 cm#1 and
1100 cm#1 for Montanox 20; 2884 cm#1, 1467 cm#1, 1341 cm#1 and
1240 cm#1 for Pluronic F127 and F108 (Fig. 4A). Concerning the
ﬁnal scaffolds spectra (Fig. 4B), they presented the characteristic
peaks of alginate at 1033 cm#1 and 1091 cm#1, corresponding to
the glucuronic (G) and the mannuronic (M) acid units, respectively.
The ##OH stretching peak was observed at 3407 cm#1. The
H##C##H and O##C##H stretching vibration was seen at
1421 cm#1. The ##COO# stretch was visible at 1609 cm#1. The
peaks at 881 cm#1 and 816 cm#1 indicated b-glycosidic linkages
between G and M units of alginates. Thus, the FTIR analysis allowed
us to demonstrate that alginate scaffolds spectra were not
contaminated by the surfactant speciﬁc peaks after the three
washing steps in a HEPES buffer.
3.4. Scaffolds’ behaviors upon hydration
Swelling behavior was followed during rehydration in a-MEM.
It was determined every 10 min for each scaffold during 150 min.
Fig. 5 shows that swelling rates were higher (around 20–40 times)
after 2 h of immersion in cell culture medium and remained stable
over time for all scaffold types (Panel A). No scaffold degradation
was observed during the experiments. Panel B shows that alginate
scaffolds preserve their morphology after rehydration. These
results suggest that the scaffold integrity was preserved during
the rehydration in cell culture medium and, therefore, that
scaffolds could support 3D cell culture.
Fig. 1. Foam stability over time of alginate foam solutions (Mx80-F, Mx20-F, F127-F
and F108-F) prepared using different stabilizing agents (Montanox 80, Montanox
20, Pluronic F127 and Pluronic F108) or without a stabilizing agent (REF).
3.5. Mechanical properties of 3D scaffolds under compression
Mechanical behaviors of rehydrated scaffolds were assessed by
3 successive compressions and their elastic moduli were deter-
mined at 50% of strain (Fig. 6). The matrices prepared in the
presence of surfactants presented lower mechanical properties in
the ﬁrst compression cycle (Mx80-S: 11 ( 2.5 kPa; Mx20-S:
22.2 ( 1 kPa; F127-S: 10.53 ( 2.6 kPa; F108-S: 15.13 ( 1.3 kPa) than
control alginate scaffolds (REF-S: 27.13 (1.43 kPa). Control alginate
scaffolds and Mx80-S presented a stable elastic modulus over the
successive compressions, which suggested an elastic behavior. On
the contrary, elastic moduli of Mx20-S, F127-S and F108-S were
time-dependent and their mechanical behaviors in compression
suggested viscous and/or plastic phenomena.
3.6. MSC seeding, viability and metabolic activity within 3D scaffolds
For in vitro experiments 20,000 human MSCs were seeded by
centrifugation on each type of scaffold. Fig. 7A shows the
distribution of cells through the thickness of the F108-S just after
seeding (4 h). As suggested by the Live/Dead1 labeling, cells were
alive and were able to be seeded through the thickness of the
scaffolds. Cell labeling and confocal microscopy observations were
similar for all the examined scaffold types, which validates the cell
seeding procedure.
Then we investigated cell metabolic activity after 3 and 14 days
of culture within the porous scaffolds using Alamar Blue Assay.
Fig. 7B shows the relative ﬂuorescence intensity measured in the
supernatant of the cell-seeded scaffolds. The results were
normalized by the ﬂuorescence intensity measured for 20,000
MSCs (the initial metabolic activity at the moment of seeding).
After 3 days of culture, a decrease in cell metabolic activity was
observed in all types of scaffolds suggesting an early cell death or a
decrease in metabolic activity. However, 14 days after seeding, the
relative ﬂuorescence intensity in all scaffolds has increased
compared to that measured for MSCs on the day of seeding,
indicating that all formulations supported long-term cell prolifer-
ation and/or increase in metabolic activity.
3.7. Secretion of paracrine factors by scaffold-seeded MSCs
Paracrine factors secreted by MSCs play a major role in
beneﬁcial effects of cell therapy. Previous studies showed that
HGF, FGF-2 and VEGF may play an important role in mediating the
beneﬁcial effects of the MSCs in cell therapy of ischemic diseases
(Efthimiadou et al., 2006; Gnecchi et al., 2008; Kitta et al., 2003;
Mias et al., 2008, 2009; Rayssac et al., 2009; Tögel et al., 2007; Xin
et al., 2001). Therefore, the functionality of MSCs was investigated
by the quantiﬁcation of HGF, FGF-2 and VEGF released in the
supernatant of MSCs cultured in alginate macroporous scaffolds.
Analyses were performed 24 h after cell seeding and the results
were compared to the secretion level obtained from MSCs in a
culture plate.
As shown in Fig. 8, we found that the secretion of HGF, FGF-2
and VEGF by the MSCs differed according to the scaffold type and
culture conditions. Cells had a tendency to down-regulate HGF and
VEGF secretions and to up-regulate FGF-2 secretion when
cultivated in 3D conditions compared to 2D culture in a culture
plate. Excepted for Mx80-S, the secretion proﬁles of the entrapped
MSCs within scaffolds prepared using surfactant seemed to be
improved in comparison with REF-S. This trend was particularly
marked for HGF secretion within Mx20-S and F127-S
Fig. 2. Morphology and porosity of macroporous scaffolds obtained with various stabilizing agents. Representative SEM images of scaffolds surfaces (Panel A to E) and cross-
sections (Panel F to J). Scale bar corresponds to 50 mm (magniﬁcation at 250$). Determination of surface (Panel K) and cross-section (Panel L) porosity and pore density of
macroporous scaffolds (measures made on 2D micro-CT images). *: p ) 0.05 and ***: p ) 0.001, based on Anova analysis.
Table 1
Porosity of the different alginate scaffolds, as determined by micro-CT analysis. The
total porosity (void volume/total volume of the ROI) is calculated from a 2D ROI
drawn within the reconstructed volume of the entire scaffold.
Samples Porosity (%)
REF-S 85.12
Mx80-S 80.06
Mx20-S 97.96
F108-S 91.98
F127-S 88.29
(1.81 (1.28 pg/ml within Mx20-S and 1.47 ( 0.69 pg/ml within
F127-S, p > 0.05 vs 0.22 ( 0.05 within REF-S) and became signiﬁ-
cant for VEGF secretion (19.31 (3.5 pg/ml within Mx20-S and
44.5 (13.04 pg/ml within F127-S, p < 0.001 vs 2.58 ( 0.5 within
REF-S).
4. Discussion
Generating high porosity in implantable scaffolds is becoming a
priority in tissue engineering and cell therapy. Indeed, an
interconnected porosity has been reported to be indispensable
for promoting good nutriment circulation, entrapped cell
Fig. 3. Micro-CT analysis of scaffolds. (A) 3D micro-CT reconstruction of a ROI of REF-S, Mx20-S and F127-S. (B) 2D micro-CT images of the cross-section of the same scaffolds.
The scale bar is 1 mm for both panels (A and B).
Fig. 4. FTIR analysis. (A) FTIR spectra and characteristic infrared peaks of surfactants: Mx80 (1), Mx20 (2), F127 (3) and F108 (4). (B) Final scaffolds FTIR spectra and
characteristic peaks: Mx80-S (1*), Mx20-S (2*), F127-S (3*), and F108-S (4*).
migration and proliferation as well as for improving the long-term
efﬁcacy of the implanted device by favoring tissue integration and
neovascularization. A consensus has been established on the
necessity to generate an interconnected porous structure with
pore size ranging from 50 to 300 mm (Mikos et al., 1993; Pittenger
and Martin, 2004). However, this range needs to be adapted to the
type of the delivered cells, to the targeted organ and to the treated
pathology.
Different strategies have been described in the literature to
obtain porosity in alginate scaffolds, particularly by utilizing
different freezing regimes (Zmora et al., 2002), adding porogens
(Hwang et al., 2010) or using foaming techniques (Eiselt et al.,
2000; Barbetta et al., 2010; Andersen et al., 2012; Sharma et al.,
2012; Bueno et al., 2014). Tailoring the porous architecture of 3D
alginate scaffolds by changing the freezing regime holds the
advantage of being a simple method however it does not allow ﬁne
control over porosity parameters (Zmora et al., 2002). In contrast,
adding porogens (Hwang et al., 2010; Sergeeva et al., 2015) and/or
using foaming techniques (Andersen et al., 2012; Barbetta et al.,
2010; Bueno et al., 2014; Eiselt et al., 2000; Sharma et al., 2012)
enable tuning additional operational parameters over hydrogels’
porosity. The latter technique appears promising in providing
highly macroporous 3D scaffolds but its real potential is yet to be
explored as the ﬁnal scaffold's biocompatibility and architecture
may be greatly affected by foam composition, foam stability and
operating conditions. The inﬂuence of parameters related to
alginate macromolecular properties (Barbetta et al., 2010;
Andersen et al., 2012, 2014a), gelling time, concentration and/or
source of gelling ions (Andersen et al., 2012) as well as to surfactant
concentration (Bueno et al., 2014; Eiselt et al., 2000) have been
extensively studied. However, the inﬂuence of surfactant type on
scaffold's characteristics has never been explored. Moreover,
although globally dedicated to cell culture (Andersen et al.,
2014b; Costantini et al., 2016), none of the previously described
foam-based scaffolds have been designed for MSC culture to match
the speciﬁc requirements of a given targeted organ and/or of a
given cell source. The present paper is the ﬁrst one to report a
comparative study of alginate foam-based scaffolds for soft tissue
engineering using MSCs. To that aim, we compared alginate
matrices with various porosities and mechanical properties
(produced using various surfactants), and shown that the scaffolds’
architecture and performance can be controlled by the type of
surfactant used.
Some protocols proposed in the literature avoid using
surfactants because of their possible toxicity; however, the
obtained porosity within the scaffold may be difﬁcult to control
in a reproducible manner. Consequently, an improvement of
mechanical properties involving the use of a potentially toxic
cross-linker (Sharma et al., 2012) may be required. In our study, we
selected non-ionic highly hydrophilic surfactants, commonly used
in biomedical applications (Andersen et al., 2012; Bueno et al.,
2014; Eiselt et al., 2000; Fowler et al., 2002; Inzana et al., 2014;
Tadros, 2005; Vashi et al., 2008), and washed them following the
preparation step to preserve the ﬁnal scaffolds’ biocompatibility.
Surfactant addition to alginate solutions appears to be an effective
strategy for stabilizing the foam and, consequently, acquiring a
homogenous porous structure after cross-linking. The use of these
surfactants enabled obtaining stable foams, for the studied period
of 120 min, thus permitting the preparation of foam-based
scaffolds with largely homogeneous porosity in all structures.
Our scaffolds, prepared using several surfactants, differed with
regard to their surface and cross-section porosity proﬁles.
Therefore, scaffolds’ microarchitectures can be controlled by
varying the surfactant type. Also, for all scaffold types, surface
porosity and pore interconnectivity allowed MSC seeding by
centrifugation.
Mechanical resistance is another critical parameter affecting
the ﬁnal device's engraftment ability and its in vivo fate. In a
previous study our group has determined, in vitro and in vivo, the
inﬂuence of alginate type on 3D alginate scaffolds biocompatibili-
ty. We have shown that G-type alginate can improve mechanical
properties of hydrogels without affecting MSC secretion capacity
(Ceccaldi et al., 2012). Based on these results, we have chosen
ultrapure G-type alginate and a high polymer concentration (3% w/
w) in order to optimize the porous structures’ mechanical
properties. Measurements of the differential elastic moduli
showed a slight loss of mechanical properties, but not signiﬁcant,
when porosity was generated in foam scaffolds (11–22 kPa) in
comparison to control alginate scaffolds (27 kPa). This range of
mechanical resistance matches soft tissues presenting elastic
moduli between 1 and 20 kPa, depending on the considered organ
(Engler et al., 2006).
Scaffolds’ FTIR spectra did not show any trace of surfactant and
their porosity supported MSC viability. The latter was maintained
during 14 days, thus showing good in vitro biocompatibility of all
alginate foam scaffolds. Furthermore, we observed that the seeded
Fig. 5. Swelling behavior. (A) Swelling ratios of Mx80-S, Mx20-S, F127-S and F108-S
as a function of sample immersion time in cell culture medium. (B) Scaffolds
morphologies after rehydration in cell culture medium.
Fig. 6. Mechanical properties of macroporous scaffolds. Determination of the
differential elastic moduli of macroporous scaffolds obtained under 3 successive
compressions (1, 2 and 3) at 50% of strain. *: p ) 0.05; **: p ) 0.01, based on two-way
Anova analysis.
cells were retained within all of the tested scaffolds. This indicates
that despite the non-cell adhesive nature of the alginate polymer,
alginate porous scaffolds could constitute an excellent support for
MSC delivery in cell therapy as they favor both cell survival and
retention. In vitro results of the secretion levels obtained from
MSCs revealed that growth factors release differed considerably
depending on the conditions of culture and scaffold type. We found
that when MSCs were grown within the scaffolds the secretion of
FGF-2 increased and that the secretion of HFG and VEGF decreased,
in comparison to cells grown in a culture plate. When comparing
MSCs’ secretory proﬁles within macroporous scaffolds, we found
that they globally improved more when a surfactant was used in
the preparation step than within control alginate scaffolds.
Interestingly, for the three studied growth factors, cell secretion
globally leveled-up more within Mx20-S and F127-S than within
REF-S. These growth factors are well known to be involved in the
positive effects of MSCs on tissue regeneration, particularly after an
ischemic injury. Indeed, HGF is known to reduce the ﬁbrotic
response and to promote both cytoprotection and angiogenesis
(Esposito et al., 2003; Jayasankar et al., 2005; Tomita et al., 2003;
Wang et al., 2004). FGF-2 and VEGF are also widely described as
being involved in blood vessels formation (Kim et al., 2011; Presta
et al., 2005; Simons, 2004; Vandervelde et al., 2005). Since the
functionality of the entrapped MSCs was best preserved within
Mx20-S and F127-S, these formulations appear as most promising
for regenerative engineering applications.
Given that surfactants generated various porous architectures
and had different impacts on MSCs’ paracrine activity, we further
examined the porous structure of the different formulations by
reconstructing a representative volume of each of them using
micro-CT. The pore sizes of all scaffolds remained within the
compatible range for 3D cell culture (50–300 mm) but notable
differences existed in their pore density. Even though MSC
metabolic activity was similar in all scaffold types, Mx20-S and
F127-S presented lower pore densities than control scaffolds, both
on surface and in cross-section. Furthermore, it was within Mx20-S
and F127-S that cell secretion of growth factors was better
preserved. Although the mechanisms responsible for the MSCs’
paracrine activity changes in scaffolds are unclear, we can
speculate that it could be related to the matrix 3D environment.
Indeed, numerous researchers have reported that the scaffold's
porosity could affect the cells’ morphology, secretory functions and
fate (Coutu et al., 2009; Dado and Levenberg, 2009; El-Ayoubi et al.,
2008; Zehbe et al., 2010). Even though all authors agree that a
highly porous and interconnected structure is necessary for the
optimal diffusion of nutrients, gases and waste, the mechanisms
responsible for the changes in cell characteristics and properties
are not fully elucidated and there is no current consensus regarding
the scaffold's optimal pore size for a given physiological process. A
recent study comparing two- and three-dimensional culture
conditions has shown that the latter enhanced the MSCs’ paracrine
immunomodulatory potential (Follin et al., 2016). Nevertheless,
such an effect strongly varies with the scaffold's morphology and
this particularity makes possible the design of tunable biomate-
rials adapted to speciﬁc application.
5. Conclusion
Our work presents for the ﬁrst time a comparative study of
various surfactants in association with alginate to generate highly
porous scaffolds matching speciﬁcations required for MSC therapy.
We used various foam stabilizing agents and compared their
inﬂuence on matrix porosity, mechanical properties and secretion
capacity of human MSCs. The range of their differential elastic
Fig. 7. Cell seeding and metabolic activity of human MSCs cultured within alginate
macroporous scaffolds. (A) Confocal z-planes (from the surface: 1 to the bottom: 10)
of MSC-seeded F108-S and a Live/Dead staining (live cells in green and dead cells in
red) 4 h after seeding. Scale bar corresponds to 200 mm (magniﬁcation at 10$). (B)
Alamar Blue assays performed 3 and 14 days after cell seeding. Results are fold to
the ﬂuorescence measured for 20,000 human MSCs in a culture plate (presented as
MSCs in the ﬁgure). * denotes a signiﬁcant difference compared to human MSCs on a
culture plate (**: p ) 0.01, ***: p ) 0.001, based on Anova analysis). (For
interpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of this article.)
Fig. 8. Paracrine activity of seeded human MSCs. Quantiﬁcation of HGF, FGF-2 and VEGF released in the supernatant by human MSCs cultured within macroporous scaffolds
or in a culture Plate 24 h post-seeding. * denotes a signiﬁcant difference compared to human MSCs in a culture plate (*: p ) 0.05; **: p ) 0.01, ***: p ) 0.001, based on Anova
analysis) and y denotes a signiﬁcant difference compared human MSCs cultured within REF-S (yyy: p ) 0.001, based on Anova analysis).
moduli corresponds to that of soft tissues and their porosity can
support cell proliferation and secretion of paracrine factors. These
results suggest that the use of foams for the preparation of alginate
scaffolds may improve the efﬁcacy of MSCs in cell therapy, as an
appropriate support for cell preservation during implantation. The
in vitro evaluation of their compatibility with MSC viability,
metabolic activity and secretion function supports the potential of
this approach for cell therapy of soft tissues.
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